MAP4K3 Antibody
- 
								中文名稱:MAP4K3兔多克隆抗體
- 
								貨號:CSB-PA013438ESR1HU
- 
								規(guī)格:¥440
- 
								圖片:
- 
								其他:
產(chǎn)品詳情
- 
											產(chǎn)品名稱:Rabbit anti-Homo sapiens (Human) MAP4K3 Polyclonal antibody
- 
											Uniprot No.:
- 
											基因名:
- 
											別名:MAP4K3 antibody; RAB8IPL1Mitogen-activated protein kinase kinase kinase kinase 3 antibody; EC 2.7.11.1 antibody; Germinal center kinase-related protein kinase antibody; GLK antibody; MAPK/ERK kinase kinase kinase 3 antibody; MEK kinase kinase 3 antibody; MEKKK 3 antibody
- 
											宿主:Rabbit
- 
											反應(yīng)種屬:Human
- 
											免疫原:Recombinant Human Mitogen-activated protein kinase kinase kinase kinase 3 protein (755-894AA)
- 
											免疫原種屬:Homo sapiens (Human)
- 
											標(biāo)記方式:Non-conjugated
- 
											克隆類型:Polyclonal
- 
											抗體亞型:IgG
- 
											純化方式:Antigen Affinity Purified
- 
											濃度:It differs from different batches. Please contact us to confirm it.
- 
											保存緩沖液:PBS with 0.02% sodium azide, 50% glycerol, pH7.3.
- 
											產(chǎn)品提供形式:Liquid
- 
											應(yīng)用范圍:ELISA, IHC
- 
											推薦稀釋比:Application Recommended Dilution IHC 1:20-1:200 
- 
											Protocols:
- 
											儲存條件:Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
- 
											貨期:Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
- 
											用途:For Research Use Only. Not for use in diagnostic or therapeutic procedures.
相關(guān)產(chǎn)品
靶點詳情
- 
											功能:May play a role in the response to environmental stress. Appears to act upstream of the JUN N-terminal pathway.
- 
											基因功能參考文獻:- hepatocellular carcinoma recurrence may involve germinal center kinase-like kinase PMID: 27343552
- Data indicate that GLK/MAP4K3 is a prognostic biomarker for non-small cell lung cancer (NSCLC) recurrence. PMID: 27203390
- Authors report that miR-199a-5p and let-7c cooperatively and efficiently inhibit HCC cell migration and invasion by targeting the metastasis promoter MAP4K3 and MAP4K3-mediated drug sensitization. PMID: 28099144
- This report details the first structure of GLK; comparison of its activation loop sequence and P-loop structure to that of Map4k4 suggests ideas for designing inhibitors that can distinguish between these family members to achieve selective pharmacological inhibitors. PMID: 27727493
- ITGB3 and MAP4K3 are directly repressed by let-7c, altering the metastatic potential of lung cancer cells. PMID: 23981581
- MAP4K3 expression is required for leucine-induced mTORC1 activation in human primary fibroblasts. PMID: 22898570
- Significantly higher median frequencies of circulating GLK-expressing T-cells were observed in patients with adult-onset Still's disease (31.85%) than in healthy volunteers (8.93%, P <0.001). PMID: 22867055
- enhanced expression in systemic lupus erythematosus PMID: 21983831
- Amino acid sufficiency phosphorylates MAP4K3/Ser170, activating mTORC1, but amino acid restriction causes MAP4K3 to interact with PP2A(T61 epsilon), promoting dephosphorylation of Ser170, MAP4K3 inhibition, and, inhibition of mTORC1 signaling. PMID: 20227368
- MAP4K3 orchestrates activation of BAX via the concerted posttranscriptional modulation of PUMA, BAD, and BIM. PMID: 19587239
 顯示更多 收起更多 
- 
											蛋白家族:Protein kinase superfamily, STE Ser/Thr protein kinase family, STE20 subfamily
- 
											組織特異性:Ubiquitously expressed in all tissues examined, with high levels in heart, brain, placenta, skeletal muscle, kidney and pancreas and lower levels in lung and liver.
- 
											數(shù)據(jù)庫鏈接:
Most popular with customers
- 
                                            
- 
                                            YWHAB Recombinant Monoclonal Antibody Applications: ELISA, WB, IHC, IF, FC Species Reactivity: Human, Mouse, Rat 
- 
                                            
- 
                                            
- 
                                            
- 
                                            
- 
                                            
- 
                                            
 
  
  
 













 
         
           
  
          